Date: February 2005.
Source: Press Announcement

ATLANTA. 3dMD, the world’s market leader in ultra-fast 3D surface imaging, is proud to announce the official launch of its 3dMDcranial™ System and its first series of clinical customers in the United States, Europe, and Australia.

3dMD is excited to report the following world-class institutions have purchased 3dMDcranial Systems.

• St. Louis Children’s Hospital at Washington University Medical Center (St Louis, United States)
• Erasmus MC University Medical Center – Sophia Children’s Hospital (Rotterdam, The Netherlands)
• Royal Children’s Hospital (Melbourne, Australia)

“We were very excited to be the customer development site for 3dMD’s latest generation 3dMDcranial System,” said Dr Alex A Kane, Assistant Professor of Surgery, Division of Plastic and Reconstructive, St. Louis Children’s Hospital at Washington University Medical Center. ” While working with 3dMD to prove and validate the 360-degree capture configuration, we have imaged hundreds of children with our 3dMD system for clinical assessment and outcome analysis purposes. We have been impressed with 3dMD’s firm commitment to the medical community.”

“Erasmus has been very focused on soft tissue analysis for a number of years and during this time we have come to truly appreciate the importance of a solid 3D imaging system that is fully productized such as our 3dMDcranial System,” said Dr Leon Van Adrichem of the CranioFacial Center Erasmus MC – Sophia Children’s Hospital in Rotterdam, The Netherlands. “Just like other 3dMD customers, we are able to fully focus on achieving our research objectives and improving patient care, without worrying whether or not we captured a good data set of the patient during the session. Based on past experiences, I know that 3dMD’s system will enable us to move our efforts forward very quickly.” (

“The 3dMDcranial System is the first of its kind in Australasia,” said John G. Meara FRACS, who is an Associate Professor at the University of Melbourne and Director of the Department of Plastic and Maxillofacial Surgery at Royal Children’s Hospital (RCH) in Melbourne, Australia. “The 3dMD system is a critical component in our outcomes research in cleft and craniofacial surgery and will facilitate multi-institutional collaboration. The RCH is presently embarking on prospective studies evaluating and linking genotype, neuropsychology assessment, speech, and language assessment and now with the 3dMD’s technology, we will incorporate craniofacial phenotype and growth.” (